CD117 and c-Kit in cancer refer to the same receptor protein, which normally responds to stem cell factor and regulates cell growth. In some tumors, abnormal KIT signaling remains active, supporting tumor survival while making the receptor relevant to diagnosis, molecular analysis, and targeted treatment.
You’ll learn how the receptor functions, which KIT mutations alter its activity, which tumors are associated with it, and how to interpret protein staining alongside gene testing.
CD117 as a Cellular Signaling Receptor
CD117 is a membrane receptor that carries a growth signal into the cell. Stem cell factor binds this receptor, which belongs to the receptor tyrosine kinase family and can activate several pathways involved in growth and survival.
The KIT gene contains the instructions for making c-KIT. Because genes supply protein-building instructions while receptors transmit cellular signals, a report that mentions either “KIT” or “c-KIT” may require you to check whether it refers to DNA, RNA, or protein.
| Name or feature | Meaning in cancer biology |
|---|---|
| CD117 | A laboratory name for the c-KIT receptor protein |
| c-KIT or KIT | The protein and its gene are often discussed together |
| Stem cell factor | The signaling molecule that activates normal KIT signaling |
| Receptor tyrosine kinase | A membrane protein that sends growth instructions into a cell |
The same name can describe 2 different laboratory findings. CD117 usually identifies protein detected by immunohistochemistry, while KIT mutation testing examines selected DNA sequences in tumor tissue.
Your report still needs careful reading because a positive stain and a detected mutation do not establish the same thing. Protein detection shows where the receptor is present; sequencing can identify an alteration affecting its function.
Normal Functions of c-KIT Signaling
Normal receptor activity supports blood formation, mast-cell development, and controlled tissue renewal. These functions begin with stem cell factor attaching to c-KIT and end when intracellular signals and cellular controls reduce the response.
Blood formation and mast cells
KIT helps regulate hematopoietic cells, the blood-forming cells produced in bone marrow. Its signaling also supports mast-cell development, including the formation of immune cells that store granules and release active substances during injury or allergic responses.
Controlled activity works more like a dimmer than an on-off switch. Stem cell factor can raise the signal, while other cellular mechanisms limit it so cells divide without receiving permission for unlimited growth.
Growth, survival, and specialization
Receptor activation starts intracellular signaling routes that influence proliferation, survival, movement, and specialization. Each route helps a developing cell respond to its environment while other signals determine whether the cell continues dividing or changes function.
- Blood-cell formation: KIT supports the development of hematopoietic cells produced in bone marrow.
- Mast-cell development: It supports immune cells whose stored granules help produce responses to injury and allergens.
- Cell survival: The pathway helps cells avoid premature death under normal physiological conditions.
- Cell specialization: It contributes to signals that help developing cells acquire particular functions.
- Controlled growth: Properly regulated activity supports tissue repair and steady cell renewal.
Too little or too much receptor activity can disturb this balance. A KIT mutation may make the protein behave as though stem cell factor remains present, allowing growth signals to continue after the original conditions have changed.
How KIT Mutations Drive Cancer
Persistent signaling can give abnormal cells a survival advantage, but a KIT alteration does not create cancer by itself. Tumor type, cooperating mutations, immune response, and tissue environment all influence the consequence.
Persistent cellular signals
Some KIT gene changes leave the receptor active without normal restraint. Repeated growth and survival messages can then help abnormal cells resist cell death and expand relative to nearby tissue.
Not every KIT mutation produces the same pattern. One alteration may act like a switch stuck in the “on” position, while another can change ligand sensitivity or affect only a particular protein region.
The mutation’s location matters because KIT contains several functional domains. A change in 1 domain may increase signaling or reduce an inhibitor’s effect, so the exact variant is more informative than the word “positive.”
| Finding | What it shows |
|---|---|
| CD117 protein expression | The receptor protein appears in sampled cells |
| KIT mutation | A genetic change is present in sampled tumor DNA |
| Mutation location | The altered region within the KIT gene |
None of these 3 findings alone describes the tumor’s full behavior. Your pathologist evaluates the specimen quality, tumor type, mutation location, and other molecular or clinical features before assigning meaning.
Cancer rarely depends on 1 genetic change alone. Additional alterations can affect cell death, immune recognition, and treatment resistance, which explains why a KIT result must be interpreted within the broader tumor profile.
Cancers Linked to KIT Abnormalities
The strongest established association involves gastrointestinal tumors, but KIT abnormalities also appear in mast-cell disorders and a smaller subset of blood cancers. Their clinical meaning depends on the disease and the alteration involved.
Gastrointestinal stromal tumors
Gastrointestinal Stromal Tumors, usually called GIST, have the strongest connection to KIT-driven biology. Many arise from interstitial cells of Cajal, specialized cells in the digestive tract wall that depend on signaling related to KIT.
CD117 expression supports recognition of many GIST tumors, although the marker is not unique to them. A stain may also appear in several blood and immune-cell disorders, so tumor structure and location remain essential for classification.
Your pathologist may combine CD117 staining with DOG1 and other findings when morphology does not establish the diagnosis. This matters because a visually similar tumor can arise in a different tissue or through a different molecular pathway.
Mastocytosis and blood cancers
Abnormal KIT activity also appears in some forms of mastocytosis, a group of conditions involving excessive mast cells. A small subset of acute myeloid leukemia cases also carries a KIT alteration, although KIT does not drive most cases of that leukemia.
The same laboratory result can carry different consequences in these diseases. A mast-cell disorder may begin as a clonal condition with variable symptoms, while a KIT alteration in acute myeloid leukemia must be evaluated within that leukemia’s classification and treatment context.
Related reading: Review the CD117-positive GIST diagnosis guide and compare CD117 and KIT mutation test methods.
Protein expression versus mutation
CD117 functions as a cancer marker only in a limited laboratory sense. A positive stain shows that antibodies detected receptor protein in the sampled tissue, not that a particular genetic change caused the tumor.
Consider a CD117-positive GIST with no detectable KIT mutation. Another tumor can contain a KIT alteration without showing strong CD117 staining, so your protein and gene results may be related without being interchangeable.
Interpreting CD117 Tests in Clinical Practice
Interpretation begins by separating protein detection from DNA analysis. A pathologist first evaluates whether the sampled cells contain c-KIT and where that protein appears, then considers whether molecular testing is needed.
Reading the tissue stain
CD117 immunohistochemistry uses labeled antibodies to locate receptor protein in a tissue section. The result records whether cells stained, the staining location, and its intensity compared with the laboratory’s controls.
Weak, patchy, or scattered staining can differ from strong, widespread staining. You should therefore review the pattern with the tumor’s cell shape, anatomical location, and other laboratory markers rather than treating staining as a simple yes-or-no result.
Sample quality can affect the result because small or damaged areas may not represent the tumor adequately. Controls can verify that the staining procedure worked, but they cannot remove uncertainty caused by heterogeneous tissue.
Criteria for molecular analysis
A tissue stain cannot reveal every sequence change in the KIT gene. Molecular analysis examines selected DNA regions for alterations that may influence classification, prognosis, or response to targeted therapy.
- Confirm the specimen: Check whether the sample contains representative tumor cells rather than only nearby tissue.
- Review the staining pattern: Record the location, strength, and distribution of detected CD117 protein.
- Compare the diagnosis: Place the marker beside the tumor’s appearance, anatomical site, and other findings.
- Identify the exact alteration: Record the KIT mutation name rather than labeling the result broadly as positive.
- Add clinical context: Interpret the finding alongside the tumor type, disease stage, and prior treatment.
- Request specialist review: Seek pathology input when classification or care depends on the result.
Don’t treat a CD117-positive stain as proof of a KIT mutation. The protein result and the gene result answer different questions.
The National Cancer Institute includes KIT among the genes and proteins studied in cancer biology. That broad role still requires a disease-specific interpretation, so your team must connect the laboratory finding with the tumor’s structure and clinical stage.
Clinical Decisions Guided by KIT Status
The exact KIT alteration matters after a tumor is identified because it can influence targeted treatment selection, response patterns, and progression. A positive stain alone cannot supply that decision-level information.
Why the exact mutation matters
A KIT alteration can influence whether a tumor responds to therapy directed at c-KIT. In GIST, for example, mutation location can affect the likelihood of response, resistance patterns, and disease progression over time.
Some KIT changes leave the receptor sensitive to targeted inhibition, while others reduce sensitivity or create different signaling activity. You need the mutation name because “KIT-positive” does not identify the altered sequence or predict a uniform response.
Mutation testing may also reveal resistance-associated changes that were not present at diagnosis. Because tumors evolve under therapy, repeat molecular assessment can become relevant when progression occurs, although the timing depends on the clinical situation.
Limits of targeted therapy
Targeted c-Kit inhibitor treatment blocks receptor-driven signals instead of attacking every rapidly dividing cell. Its value depends on the tumor type, exact alteration, disease setting, and prior treatment.
Imatinib is a KIT inhibitor used in selected settings, including treatment of GIST. Its role is not interchangeable with every c-KIT inhibitor, and a CD117-positive stain by itself does not establish that Imatinib is appropriate.
Response can change when a cancer develops additional genetic changes. An oncology team can therefore combine sequencing, imaging, symptoms, prior response, and disease stage rather than relying on receptor staining as the sole basis for treatment.
Have a pathologist or oncology team review the tissue diagnosis, CD117 pattern, exact KIT alteration, and disease stage together.
Your combined review prevents 1 laboratory detail from carrying more meaning than it deserves. It also avoids assuming that every CD117-positive tumor shares the same biology or responds to the same targeted drug.
Key Takeaways for CD117 and KIT Testing
CD117 and c-KIT identify the same receptor, while the KIT gene supplies its instructions. Abnormal signaling can support several cancers, but protein expression, mutation status, and mutation location remain separate findings.
Your most useful interpretation combines the stain with the tumor type, specimen quality, exact sequence result, disease stage, and treatment history. Imatinib and other c-Kit inhibitors depend on those details rather than on CD117 positivity alone.
FAQ
Is CD117 the same thing as c-Kit?
Yes. CD117, c-KIT, and the KIT protein name the same receptor. CD117 can also refer to a laboratory stain showing where the receptor appears in tissue, while KIT may refer to the gene carrying the instructions for making it.
What is the normal function of the c-Kit receptor?
The c-KIT receptor responds to stem cell factor and helps regulate blood-cell formation, mast-cell development, growth, survival, and specialization. Its effects depend on controlled activation and deactivation within a healthy cellular environment.
How is CD117 related to cancer?
CD117 itself is a normal cellular protein, not inherently a sign of cancer. Its importance arises when tumor cells express it, especially alongside an activating KIT change that may send persistent growth and survival signals through the same pathway.
Does CD117 staining prove that a KIT mutation exists?
No. CD117 immunohistochemistry detects the receptor protein in sampled tissue. Molecular analysis is needed to identify a KIT gene change, and your pathologist must interpret protein expression alongside the tumor’s structure and other findings.
Which cancers are associated with c-Kit expression or KIT mutations?
Gastrointestinal Stromal Tumors have the strongest established connection. KIT abnormalities also occur in some cases of mastocytosis, acute myeloid leukemia, and other less frequent tumors, but each condition carries a different clinical meaning.
How do c-Kit inhibitors work in cancer care?
c-Kit inhibitors block signaling from the receptor. Their usefulness depends on the cancer and the exact KIT alteration because some tumors respond while others resist or develop resistance. An oncology team must interpret the result alongside disease stage and prior care.
